Bioburden Testing for Medical Devices India | NABL Accredited

Auriga Research provides NABL-accredited bioburden testing for medical devices per ISO 11737-1. Our microbiology laboratory performs pre-sterilisation bioburden enumeration, recovery efficiency validation, and microbial characterisation to support sterilisation validation dossiers for CDSCO, FDA 510(k), and CE marking submissions.

Bioburden data is the foundation of sterilisation process design. Accurate enumeration ensures sterilisation doses and cycle parameters deliver the required Sterility Assurance Level (SAL of 10^-6). We test implants, surgical instruments, wound dressings, catheters, syringes, and all classes of medical devices.

Bioburden Testing Scope

Total aerobic microbial count (TAMC) per ISO 11737-1
Total yeast and mould count (TYMC)
Recovery efficiency validation (repetitive and corrective)
Microbial identification — genus/species by biochemical or molecular methods
Routine bioburden monitoring for production batch release
Bioburden trending and SPC analysis for process control
Raw material and component bioburden assessment

Who Needs Bioburden Testing

Medical device manufacturers establishing sterilisation validation
Contract sterilisers requiring bioburden data for dose audits
Companies filing CDSCO, FDA 510(k), or CE technical files
Quality teams monitoring production bioburden trends
Implant and surgical instrument manufacturers

Turnaround Time

Standard bioburden enumeration takes 7-10 business days (including incubation periods). Recovery efficiency validation takes 15-20 business days. Microbial identification adds 5-7 business days. Routine batch release bioburden is typically reported within 7 days.

Related Services

Frequently Asked Questions

What is bioburden testing and why is it required for medical devices?

Bioburden testing determines the total number of viable microorganisms on a medical device prior to sterilisation. Per ISO 11737-1, bioburden data is essential for establishing and validating sterilisation processes — it defines the microbial challenge the sterilisation cycle must overcome. CDSCO, FDA, and CE marking all require bioburden testing as part of the sterilisation validation dossier for medical devices.

How is bioburden testing performed per ISO 11737-1?

The device or representative portion is subjected to extraction using rinse, sonication, or stomaching techniques to remove microorganisms from surfaces. The extract is then cultured on appropriate media (TSA for bacteria, SDA for fungi) and incubated at prescribed temperatures. Colony counts represent the bioburden level. Method validation — including recovery efficiency determination — must be performed to demonstrate the extraction technique recovers a known proportion of organisms.

What is an acceptable bioburden level for medical devices?

There is no universal pass/fail bioburden limit — acceptable levels depend on the sterilisation method and required Sterility Assurance Level (SAL). For EO and radiation sterilisation, bioburden data feeds into dose-setting calculations (e.g., ISO 11137 VDmax method). Devices with consistently low bioburden (under 10 CFU) can qualify for lower sterilisation doses. Monitoring bioburden trends over production batches is equally important for process control.